Compare RZLT & CION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RZLT | CION |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | 71 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.6M | 384.8M |
| IPO Year | 2011 | 2011 |
| Metric | RZLT | CION |
|---|---|---|
| Price | $3.35 | $6.62 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $9.67 | $7.00 |
| AVG Volume (30 Days) | ★ 1.3M | 560.9K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.96% |
| EPS Growth | ★ 26.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.55 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $6.50 |
| 52 Week High | $11.46 | $10.93 |
| Indicator | RZLT | CION |
|---|---|---|
| Relative Strength Index (RSI) | 53.29 | 33.30 |
| Support Level | $2.93 | $6.55 |
| Resistance Level | $3.60 | $7.91 |
| Average True Range (ATR) | 0.21 | 0.23 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 68.55 | 5.56 |
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Companies portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.